Risk Factors for Peripheral Arterial Disease Among Patients With Chronic Kidney Disease

Tulane University School of Medicine, New Orleans, LA, USA.
The American journal of cardiology (Impact Factor: 3.28). 03/2012; 110(1):136-41. DOI: 10.1016/j.amjcard.2012.02.061
Source: PubMed

ABSTRACT Patients with chronic kidney disease (CKD) have an increased risk for developing peripheral arterial disease (PAD). The aim of this study was to examine the cross-sectional association between novel risk factors and prevalent PAD in patients with CKD. A total of 3,758 patients with estimated glomerular filtration rates of 20 to 70 ml/min/1.73 m(2) who participated in the Chronic Renal Insufficiency Cohort (CRIC) study were included in the present analysis. PAD was defined as an ankle-brachial index <0.9 or a history of arm or leg revascularization. After adjustment for age, gender, race, cigarette smoking, physical activity, history of hypertension and diabetes, pulse pressure, high-density lipoprotein cholesterol, estimated glomerular filtration rate, and CRIC clinical sites, several novel risk factors were significantly associated with PAD. For example, odds ratios for a 1-SD higher level of risk factors were 1.18 (95% confidence interval [CI] 1.08 to 1.29) for log-transformed high-sensitivity C-reactive protein, 1.18 (95% CI 1.08 to 1.29) for white blood cell count, 1.15 (95% CI 1.05 to 1.25) for fibrinogen, 1.13 (95% CI 1.03 to 1.24) for uric acid, 1.14 (95% CI 1.02 to 1.26) for glycosylated hemoglobin, 1.11 (95% CI 1.00 to 1.23) for log-transformed homeostasis model assessment of insulin resistance, and 1.35 (95% CI 1.18 to 1.55) for cystatin C. In conclusion, these data indicate that inflammation, prothrombotic state, oxidative stress, insulin resistance, and cystatin C were associated with an increased prevalence of PAD in patients with CKD. Further studies are warranted to examine the causal effect of these risk factors on PAD in patients with CKD.

10 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral arterial disease (PAD) is underdiagnosed, undertreated, and increasing in prevalence. Continued advances in understanding atherosclerosis, pathophysiology of vascular disease and risk factor modification emphasize the importance of a complete medical regimen. With the recently changed guidelines for PAD suggesting screening patients at an earlier age and the known benefits of using preventive therapies for PAD, this is the perfect time to review recent information and research on medical therapy for PAD, both for symptomatic patients and for secondary prevention. PAD is a manifestation of systemic atherosclerosis. With the recent update of the ACC/AHA guidelines for the management of PAD, risk factor modification continues to be a major focus. Smoking is one of the most important modifiable risk factors in patients with PAD. New recommendations and therapeutic options exist for assisting patients in smoking cessation. Additionally, new evidence continues to support controlling hypertension, controlling lipids and use of antiplatelet agents. Evidence continues to evolve about the evidence of exercise therapy in symptomatic and asymptomatic PAD. PAD is associated with increased risk of cardiovascular morbidity and mortality. Medical therapy is targeted toward systemic atherosclerosis and risk factor modification. Exercise therapy is the most studied and validated therapy for symptomatic peripheral arterial disease.
    Current opinion in cardiology 10/2012; 27(6):592-7. DOI:10.1097/HCO.0b013e328357428a · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We determined the prevalence of asymptomatic peripheral arterial disease (PAD) and cardiovascular risk factors in Taiwan. Ambulatory participants (n = 1915) without symptoms of PAD were enrolled (mean age of 61.2 years). The ankle-brachial index (ABI) was used to detect the PAD (ABI < 0.90). The overall prevalence of asymptomatic PAD was 5.4% (2.8% in the younger participants [<65 years of age, n = 1021] and 8.4% in the elderly participants [≥65 years of age, n = 894]). Younger participants with asymptomatic PAD had a significantly higher rate of hypertension (55.2% vs 30%) and obesity (31% vs 13.3%) than those without asymptomatic PAD (P < .05). Elderly participants with asymptomatic PAD had a significantly higher rate of diabetes mellitus (36% vs 21.2%) and hypertension (69.3% vs 55.4%) than those without asymptomatic PAD (P < .05). Asymptomatic PAD is prevalent among elderly Taiwanese individuals. Overall, age was the strongest risk factor for the development of asymptomatic PAD.
    Angiology 03/2013; 65(5). DOI:10.1177/0003319713480842 · 2.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The prevalence of renal posttransplantation amputation and its impact on allograft and patient survival have not been widely reported. Methods: We used an incident cohort of patients who underwent renal transplantation between June 2004 and September 2009. Amputation data were obtained using Medicare institutional claim forms. Baseline demographics and comorbidities, such as peripheral vascular disease (PVD), diabetes, ischemic heart disease, cerebrovascular disease, hypertension, and smoking, were captured. The chi-square and t tests were used for statistical associations. Kaplan-Meier survival curves were plotted for renal allograft and patient survival. Independent associations between patient factors and amputation were examined using multivariable Cox regression analysis. Results: Of the 85,873 renal transplant recipients, 1062 patients had amputation. The prevalence of amputation was higher in those with PVD versus those without PVD at listing (5.6% vs. 1%; P=0.0001). Mean allograft survival was 55.5±0.55 months in patients with amputation versus 60.6±0.06 months in patients without amputation (P=0.0001). All-cause mortality was higher in patients with amputation versus those without amputation (19.9% vs. 7.3%; P=0.0001). Mean allograft survival was 60.97±0.67 months in non-African Americans without amputation versus 55.7±0.65 months in non-African Americans with amputation. Allograft survival was 59.73±0.13 months in African Americans without amputation versus 54.9±1.06 months in African Americans with amputation. In patients with amputation, race did not have any impact. Infectious complications were noted in 39 patients leading to death. Conclusions: Amputation is associated with decreased allograft and patient survival. Early detection and preventive strategies for PVD may decrease amputation rate and improve survival.
    Transplantation 04/2013; 95(10). DOI:10.1097/TP.0b013e31828e72b4 · 3.83 Impact Factor
Show more